Breaking News Instant updates and real-time market news.

DIS

Disney

$112.89

1.13 (1.01%)

, SFM

Sprouts Farmers Market

$22.02

1.14 (5.46%)

12:05
03/20/17
03/20
12:05
03/20/17
12:05

On The Fly: Top stock stories at midday

Stocks opened little changed and have moved in a narrow range all morning with little in the way of a catalyst to give the market direction. Although the Trump rally is exhibiting cracks, it has not broken down yet. Oil prices have resumed their downtrend, sliding about 1% near noon and struggling to stay above the $48 a barrel level. ECONOMIC EVENTS: In the U.S., the Chicago National Activity index rose to 0.34 in February after dipping to -0.02 in January. In Europe, the U.K. said it will formally trigger its exit from the EU on March 29. Triggering Article 50 of the Lisbon Treaty, the formal procedure for leaving the bloc, will open a two-year timetable for negotiations, with Britain able to leave the EU by 2019. COMPANY NEWS: Walt Disney's (DIS) "Beauty and the Beast," the latest in a string of live-action remakes of animated classics from the company, topped box offices with a record-breaking $170M launch in the U.S. alongside $180M from international markets. Shares of Disney have gained 1% to $112.84 near noon... Shares of Sprout Farmers Market (SFM), which had jumped about 25% last week, are little changed at midday after Bloomberg reported that Cerberus Capital-backed Albertsons has held preliminary merger talks with the company. Shares of its larger competitor Whole Foods Market (WFM) are up about 1% following the news... Snap (SNAP) has landed its first Buy rating this morning. Monness Crespi analyst James Cakmak initiated the stock with a Buy saying he is prepared to "give the benefit of the doubt" to the parent of Snapchat. The shares have advanced about 1.5%. MAJOR MOVERS: Among the notable gainers was Nektar Therapeutics (NKTR), which advanced about 30% after the company said that a late-stage trial of NKTR-181, which was previously granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of moderate to severe chronic pain, met the primary and secondary endpoints. Also higher was CytomX Therapeutics (CTMX), which gained about 24% after announcing an expansion of the company's strategic collaboration with Bristol-Myers Squibb (BMY). Additionally, Esperion Therapeutics (ESPR) jumped 50% after the company announced that the FDA confirmed that the bempedoic acid phase 3 program is adequate to support approval of an LDL-C lowering indication prior to outcomes data. Among the noteworthy losers was Movado (MOV), which slid about 2% after the company announced weak guidance and a reduction in its workforce. Also lower was Array Biopharma (ARRY), which slipped 7% after the company withdrew its FDA application for binimetinib in a rare subset of skin cancer. INDEXES: Near midday, the Dow was up 24.73, or 0.12%, to 20,939.35, the Nasdaq was up 5.33, or 0.09%, to 5,906.32, and the S&P 500 was down 1.39, or 0.06%, to 2,376.86.

DIS

Disney

$112.89

1.13 (1.01%)

SFM

Sprouts Farmers Market

$22.02

1.14 (5.46%)

WFM

Bought by AMZN

$29.53

0.06 (0.20%)

SNAP

Snap

$19.80

0.26 (1.33%)

NKTR

Nektar

$15.50

-0.21 (-1.34%)

CTMX

CytomX Therapeutics

$15.18

0.18 (1.20%)

BMY

Bristol-Myers

$56.52

0.23 (0.41%)

MOV

Movado

$22.95

-0.65 (-2.75%)

ARRY

Array BioPharma

$10.56

-0.18 (-1.68%)

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 01

    Apr

  • 27

    Apr

  • 20

    Jun

  • 30

    Jun

DIS Disney
$112.89

1.13 (1.01%)

03/20/17
PIPR
03/20/17
NO CHANGE
Target $130
PIPR
Overweight
Disney's Beauty and the Beast topped expectations, says Piper Jaffray
Piper Jaffray analyst Stan Meyers says Disney's Beauty and the Beast topped expectations this weekend with a domestic opening of $170M, ahead of his $130M-$140M estimate and industry tracking of $125M. He now expects the film to cross the $450M mark domestically, ahead of his $400M estimate. Meyers remains a buyer of Disney shares with an Overweight rating and $130 price target.
03/14/17
GUGG
03/14/17
UPGRADE
Target $128
GUGG
Buy
Disney upgraded to Buy from Neutral at Guggenheim
Guggenheim analyst Michael Morris upgraded Disney to Buy from Neutral saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118.
03/14/17
03/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris upgraded saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118. 2. Dick's Sporting (DKS) upgraded to Outperform from Peer Perform at Wolfe Research. 3. Quest Diagnostics (DGX) upgraded to Conviction Buy from Buy at Goldman with analyst Isaac Ro saying the company should be a key beneficiary as the U.S. healthcare system shifts the cost burden to the individual and creates price transparency for the first time. 4. Olympic Steel (ZEUS) and Reliance Steel (RS) were upgraded to Outperform from Neutral at Macquarie, while Worthington (WOR) was upgraded to Neutral from Underperform. 5. Ethan Allen (ETH) upgraded to Strong Buy from Market Perform at Raymond James with analyst Budd Bugatch double upgrading the company saying sales comparisons get easier through 2017 while the retailer's remerchandising effort is behind it, thereby lowering the clearance markdowns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/16/17
PIPR
03/16/17
NO CHANGE
Target $130
PIPR
Overweight
Piper more confident after seeing Disney's Beauty and the Beast
Piper Jaffray analyst Stan Meyers says he left a screening of Disney's Beauty and the Beast more confident in his $900M global box office forecast. The analyst admits the film's 68% Rotten Tomatoes score is an issue, but he believes limited competition over the next few weeks and the film's darker undertone to broaden the target audience should secure "strong staying power" after the opening. He expects the movie to open in the $130M-$140M range. Meyers keeps an Outperform rating on Disney.
SFM Sprouts Farmers Market
$22.02

1.14 (5.46%)

03/20/17
JEFF
03/20/17
NO CHANGE
Target $22
JEFF
Buy
Jefferies sees $26/share buyout price for Sprouts Farmers Market
After Bloomberg reported that Cerberus Capital Management-backed Albertsons held preliminary talks to merge with Sprouts Farmers Market, Jefferies analyst Christopher Mandeville says historical transactions suggest a $26 per share takeout price for Sprouts. The stock in pre-market trading is up 5%, or $1.13, to $23.15. If Sprouts is willing to sell itself, multiple suitors, both financial and strategic, could show interest, leading to a competitive bidding process that could potentially push the valuation higher than $26 per share, Mandeville tells investors in a research note. The company, as one of the last few growth concepts remaining in grocery, should "receive a very healthy valuation," the analyst argues. He has a Buy rating on Sprouts with a $22 price target.
02/27/17
RBCM
02/27/17
NO CHANGE
RBCM
Sprouts Farmers Markets fiscal 2017 guidance conservative, says RBC Capital
After Sprouts reported stronger than expected results, RBC Capital analyst William Kirk says that the company's fundamentals continue to be strong. He thinks that the company's guidance is "beatable," partly due to easing comps and lessening cannibalization, along with the contribution of the company's new stores to comp increases. Kirk remains upbeat on the company's fundamentals and keeps an Outperform rating on the shares.
02/02/17
FBCO
02/02/17
NO CHANGE
Target $23
FBCO
Outperform
Re-inflation to alleviate Sprouts Farmers Markets pressure, says Credit Suisse
Credit Suisse analyst Edward Kelly says that while short-term caution is certainly warranted given accelerating produce deflation and a tough overall competitive environment, he thinks Sprouts Farmers Markets' Q4 will eventually result in an attractive opportunity. The analyst believes the stock may be the most leveraged to re-inflation at this point, as comps should see relief when pricing firms, margin pressure should moderate as industry promotions begin to ease, and the valuation has upside given it is likely to remain a growth story. He reiterates an Outperform rating and $23 price target on the shares.
02/01/17
OTRG
02/01/17
UPGRADE
OTRG
Mixed
Sprouts Farmers Markets upgraded to Mixed from Negative at OTR Global
OTR Global changed its view on Sprouts Farmers Markets to Mixed following checks that indicate orders improved slightly in Q4 due to promotions.
WFM Bought by AMZN
$29.53

0.06 (0.20%)

02/02/17
CLVD
02/02/17
NO CHANGE
CLVD
Whole Foods estimate lowered on softenting trends at Cleveland Research
02/09/17
PIVT
02/09/17
NO CHANGE
Target $20
PIVT
Sell
Pivotal calls Whole Foods sales deceleration 'alarming'
Pivotal Research analyst Ajay Jain believes Whole Foods' sales are decelerating at an "alarming rate." The company's guidance reduction last night is the latest in a multi-year string of earnings setbacks, Jain tells investors in a post-earnings research note. He keeps a Sell rating on the shares with a $20 price target.
02/09/17
FBCO
02/09/17
NO CHANGE
Target $36
FBCO
Outperform
Whole Foods price target lowered to $36 from $40 at Credit Suisse
Credit Suisse analyst Edward Kelly lowered his price target for Whole Foods to $36 from $40 following the company's mixed Q1 earnings update. The analyst reiterates an Outperform rating on the shares as he continues to see value in the brand, believes there is a path for improved performance over time, and likes the stock's risk/reward.
01/20/17
01/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Aegis. 2. Alphabet (GOOG, GOOGL) and Facebook (FB) were resumed with an Overweight at Pacific Crest, while Twitter (TWTR) was resumed with a Sector Weight. 3. Costco (COST) coverage was resumed with a Buy at Stifel, while Wal-Mart (WMT) and Target (TGT) were resumed with a Hold. 4. Whole Foods (WFM) was initiated with a Market Perform, while Sprouts Farmers Markets (SFM) was initiated with an Outperform at William Blair. 5. CBS (CBS) was reinstated with an Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SNAP Snap
$19.80

0.26 (1.33%)

03/17/17
03/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with an Outperform at Bernstein. 2. Snap (SNAP) initiated with a Neutral at Mizuho. 3. Cantel Medical (CMD) initiated with a Market Perform at Raymond James. 4. Hilton (HLT) reinstated with an Overweight at JPMorgan. 5. Regeneron (REGN) initiated with a Perform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/17
MONN
03/20/17
INITIATION
Target $25
MONN
Buy
Snap initiated with a Buy at Monness Crespi
Monness Crespi analyst James Cakmak initiated Snap with a Buy and a $25 price target.
03/17/17
MZHO
03/17/17
INITIATION
Target $20
MZHO
Neutral
Snap initiated with a Neutral at Mizuho
Mizuho analyst Neil Doshi started Snap Inc. with a Neutral rating and $20 price target.
03/20/17
03/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Monness Crespi analyst James Cakmak initiated Snap (SNAP) with a Buy and a $25 price target. 2. Workday (WDAY) initiated with a Buy at BofA/Merrill. 3. Berkshire Hathaway (BRK.A) initiated with an Equal Weight at Morgan Stanley. 4. MeetMe (MEET) initiated with a Buy at Canaccord. 5. ARC Document (ARC) resumed with a Buy at B. Riley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NKTR Nektar
$15.50

-0.21 (-1.34%)

03/20/17
PIPR
03/20/17
NO CHANGE
Target $29
PIPR
Overweight
Nektar price target raised to $29 after opioid trial success at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he thought prospects of success for NKTR-181 were very low after a failed Phase 2 study but he was "happy to be proven wrong" after the SUMMIT trial succeeded. A human abuse liability study will read-out around mid-2017, after which the company will meet with the FDA to discuss whether the package for NKTR-181 is adequate for filing, Schimmer noted. He raised his price target on Nektar shares to $29 from $25 and keeps an Overweight rating on the stock, which he calls his "top mid-cap biotech stocks for other reasons," such as its multiple royalty streams from partnered products and its emerging immuno-oncology platform.
01/06/17
BTIG
01/06/17
INITIATION
Target $22
BTIG
Buy
Nektar initiated with a Buy at BTIG
BTIG analyst Robert Hazlett started Nektar Therapeutics with a Buy rating and $22 price target. Several "intriguing" emerging therapeutics along with multiple near-term catalysts make the shares attractive, Hazlett tells investors in a research note.
01/03/17
JANY
01/03/17
NO CHANGE
JANY
Janney sees pricing, rising rates as biotech headwinds in 2017
Janney Capital analyst Debjit Chattopadhyay noted that, on a relative basis vs. the Nasdaq, 2016 was the worst year for the Nasdaq biotechnology index (NBI) since 1994 and he believes the "outlook for 2017 isn't particularly rosy" given structural challenges for the sector along with rising interest rates. He cautions about overenthusiasm on M&A, as Chattopadhyay thinks "cash rich pharma may choose to return cash to shareholders through increased buybacks and dividends," and he believes "M&A, if any, is likely to lead to short-term relief rallies and may not represent a broader turn in sentiment." Meanwhile, broader discussion on healthcare spending and regulatory changes are likely to be bigger drivers of biotech sentiment during 2017 than M&A, said Chattopadhyay, who listed bluebird bio (BLUE), Galapagos NV (GLPG), Vertex (VRTX), Clovis (CLVS) and Nektar (NKTR) as on the firm's 2017 biotechnology focus list.
01/26/17
PIPR
01/26/17
NO CHANGE
PIPR
Overweight
Celgene acquisition highlights underappreciated Nektar asset, says Piper Jaffray
After Celgene (CELG) announced this morning a deal to acquire Delinia for $300M plus up to $475M in potential milestones, Piper Jaffray analyst Joshua Schimmer noted that the company's lead asset, DEL106, being developed for autoimmune disorders, is similar to Nektar's (NKTR) NKTR-358. While many investors are familiar with Nektar's immune-oncology program, NKTR-214, far fewer are familiar with NKTR-358, though both represent potential blockbuster opportunities if successful, Schimmer tells investors. He keeps an Overweight rating on Nektar, which he identifies as one of his top mid-cap picks.
CTMX CytomX Therapeutics
$15.18

0.18 (1.20%)

03/20/17
NOMU
03/20/17
NO CHANGE
Target $32
NOMU
Buy
CytomX Therapeutics price target raised to $32 from $21 at Nomura
01/03/17
OPCO
01/03/17
DOWNGRADE
OPCO
Perform
CytomX Therapeutics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann downgraded CytomX Therapeutics to Perform citing valuation. The analyst's model assumes only one of the company's experimental therapies has a revenue impact between 2016 and 2025.
03/01/17
NOMU
03/01/17
INITIATION
Target $21
NOMU
Buy
CytomX Therapeutics initiated with a Buy at Nomura
Nomura initiated CytomX Therapeutics with a Buy and a $21 price target.
BMY Bristol-Myers
$56.52

0.23 (0.41%)

02/01/17
GSCO
02/01/17
NO CHANGE
GSCO
Bristol-Myers estimates trimmed for Sprycel loss at Goldman
Goldman reduced Bristol-Myers earnings estimates by 4c-7c for 2017-2021 to reflect the lost of the Sprycel appeal in the EU. The firm continues to rate Bristol-Myers a Buy.
02/15/17
DBAB
02/15/17
NO CHANGE
DBAB
Deutsche not seeing Pfizer buying Bristol-Myers at this time
Following yesterday's speculation of a potential deal, Deutsche Bank analyst Gregg Gilbert said he would be surprised to see Pfizer (PFE) make a move on Bristol-Myers Squibb (BMY) at this stage. Such an acquisition "would represent a very large and concentrated opportunity/risk on immuno-oncology, an area fraught with near-term uncertainty," Gilbert told investors last night in a research note. He believes that if Pfizer were to use $90B for a deal, it would prefer to acquire a more diverse set of value drivers. The analyst keeps a Hold rating on Bristol and Buy rating on Pfizer. Bristol shares rose 3% yesterday to $53.71 amid speculation of a potential takeover. The conjecture had Roche (RHHBY), Novartis (NVS) and Pfizer potentially looking into a bid for Bristol.
03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
03/06/17
FBCO
03/06/17
NO CHANGE
FBCO
Near-Term acquisition of Bristol-Myers unlikely, says Credit Suisse
Credit Suisse analyst Vamil Divan says there is increasing investor focus on strategic actions and opportunities around Bristol-Myers (BMY) following the company's recent stumbles and the increased stake activist investors have taken in the stock. The analyst notes that "the big question" remains whether any of its peers may be interested in an outright acquisition, with Pfizer (PFE), Novartis (NVS) and Gilead (GILD) among the possible acquirers. While the numbers may make sense, Divan sees an acquisition in the next 9-12 months as unlikely as he needs more clarity on some of the large unknowns in the lung cancer market and macro issues such as corporate tax reform.
MOV Movado
$22.95

-0.65 (-2.75%)

12/15/16
SIDC
12/15/16
DOWNGRADE
Target $34
SIDC
Neutral
Movado downgraded to Neutral from Buy at Sidoti
Sidoti analyst Frank Camma downgraded Movado Group to Neutral citing valuation and the "tepid" retail environment. The analyst keeps a $34 price target for the shares.
01/30/17
SIDC
01/30/17
UPGRADE
SIDC
Buy
Movado upgraded to Buy from Neutral at Sidoti
Sidoti analyst Frank Camma upgraded Movado to Buy and maintained its $34 price target saying recent retail weakness is reflected in price and tariff concerns are overblown.
01/30/17
01/30/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) and Madison Square Garden (MSG) were upgraded to Overweight from Equal Weight at Morgan Stanley. 2. Dick's Sporting (DKS) upgraded to Buy from Neutral at Goldman with analyst Stephen Tanal saying he believes Dick's is well positioned in a post The Sports Authority world and will reap the rewards of consolidation through sales and earnings growth driven by share gains and improved product allocations from key vendors. Further, Dick's is transitioning to a fully in-sourced eCommerce operation, which should drive improved profitability. 3. American Express (AXP) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Sanjay Sakhrani citing improved fundamentals and visibility. "The low end of the company's 2017 earnings guidance is 'very achievable' just through stated operating cost reductions and capital management, and any revenue growth represents upside potential," Sakhrani tells investors in a research note. He raised his price target for American Express shares to $91 from $81. 4. Royal Caribbean (RCL) upgraded to Buy from Hold at Argus with analyst John Staszak says the company has "few competitors and strong market opportunities." He expects it to benefit from lower costs and increased international demand going forward. 5. Movado (MOV) upgraded to Buy from Neutral at Sidoti with analyst Frank Camma saying recent retail weakness is reflected in price and tariff concerns are overblown. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/16
SIDC
11/22/16
NO CHANGE
Target $34
SIDC
Buy
Movado price target raised to $34 from $29 at Sidoti
Sidoti analyst Frank Camma raised his price target for Movado to $34 from $29 on "solid" Q3 earnings, newly introduced 2018 estimates and the announcement of a new licensed fashion brand. The analyst is impressed by the company's ability to produce a "solid" gross margin in light of a tepid retail landscape and pressures to discount prices. Additionally, Camma sees the signing of the Rebecca Minkoff fashion brand as an incremental approach to gain traction with millennial consumers. He reiterates a Buy rating on the shares.
ARRY Array BioPharma
$10.56

-0.18 (-1.68%)

03/20/17
LEER
03/20/17
NO CHANGE
Target $9
LEER
Market Perform
Binimetinib NDA withdrawal 'a clear setback' for Array BioPharma, says Leerink
Leerink analyst Michael Schmidt notes that Array BioPharma announced it has withdrawn its new drug application for binimetinib in NRAS+ melanoma following recent FDA interactions since results of the Phase 3 trial do not support regulatory approval. While NRAS+ melanoma was only a small value driver for the company, the analyst thinks this comes as a surprise to investors and is "a clear setback" for Array and management's regulatory and commercial strategy. He reiterated a Market Perform rating on the stock, and lowered his price target on the shares to $9 from $11.
03/20/17
WELS
03/20/17
NO CHANGE
WELS
Array chances in BRAF not impacted by NRAS melanoma withdrawal, says Wells Fargo
After Array BioPharma withdrew its application for FDA approval of its binimetinib drug as an NRAS mutant melanoma treatment following a meeting with the agency, Wells Fargo does not think the withdrawal impacts the chances of the drug succeeding as a treatment for BRAF melanoma. Wells says that the BRAF indication is larger, while the benefit of the drug is also greater in that indication and it appears to be best in class. Wells trimmed its price target on Array to $13-$15 from $16-$18 but keeps an Outperform rating on the shares.
03/20/17
JPMS
03/20/17
NO CHANGE
Target $9
JPMS
Neutral
JPMorgan sees Array down 5%-10% on withdrawal news
JPMorgan analyst Anupam Rama says Array BioPharma's withdrawal of its new drug application filing for binimetinib in NRAS melanoma is a surprise. The analyst lowered his price target for the shares to $9 from $10 and thinks the stock today could be down 5%-10%. The analyst notes that NRAS melanoma only contributed around $100M in peak sales and $1 per share to his model. Rama keeps a Neutral rating on Array. The stock in premarket trading is down 14%, or $1.41, to $9.15.
03/20/17
COWN
03/20/17
NO CHANGE
Target $14
COWN
Outperform
Array BioPharma weakness a buying opportunity, says Cowen
Cowen analyst Chris Shibutani said Array's decision to withdraw its application for binimetinib monotherapy for the treatment of NRAS-mutant melanoma was prudent given the known modest efficacy benefit. He views the decision as a de-risking event and said weakness in the shares is a buying opportunity. Shibutani reiterated his Outperform rating and lowered his price target to $14 from $15 on Array Biopharma shares.

TODAY'S FREE FLY STORIES

02:35
11/23/17
11/23
02:35
11/23/17
02:35
General news
FX Update: The dollar has remained on a downward path »

FX Update: The dollar…

L

Loews

$49.36

-0.02 (-0.04%)

, GE

General Electric

$18.15

0.32 (1.79%)

18:41
11/22/17
11/22
18:41
11/22/17
18:41
Hot Stocks
Loews CEO James Tisch buys 3M shares of General Electric »

In a regulatory filing,…

L

Loews

$49.36

-0.02 (-0.04%)

GE

General Electric

$18.15

0.32 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$12.77

-0.16 (-1.24%)

18:06
11/22/17
11/22
18:06
11/22/17
18:06
Hot Stocks
BRF S.A. names Jose Aurelio Drummond Jr. as CEO »

BRF S.A. hereby informs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$35.42

0.2 (0.57%)

18:02
11/22/17
11/22
18:02
11/22/17
18:02
Hot Stocks
Suncor closes sale of equity interest in East Tan Farm, redeems $750M in debt »

Suncor successfully…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SAP

SAP

$113.85

-1.44 (-1.25%)

17:53
11/22/17
11/22
17:53
11/22/17
17:53
Periodicals
SAP launches investigation of sales practices in Gulf region, Reuters reports »

SAP has launched a formal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$180.87

-0.99 (-0.54%)

17:47
11/22/17
11/22
17:47
11/22/17
17:47
Periodicals
Facebook tool to show users which content was Russian propaganda, says Bloomberg »

Facebook will add a tool…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$51.01

0.79 (1.57%)

17:24
11/22/17
11/22
17:24
11/22/17
17:24
Periodicals
CSX to charge more fees on customers that disregard shipping rules, Reuters says »

Starting on January 1st,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AYTU

Aytu BioScience

$3.03

0.4301 (16.54%)

17:10
11/22/17
11/22
17:10
11/22/17
17:10
Syndicate
Breaking Syndicate news story on Aytu BioScience »

Aytu BioScience files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPIX

ESSA Pharma

$0.27

0.0059 (2.27%)

17:09
11/22/17
11/22
17:09
11/22/17
17:09
Hot Stocks
ESSA Pharma to begin trading on TSX Venture Exchange »

ESSA Pharma is listing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRDN

Meridian Waste Solutions

$1.69

0.0101 (0.60%)

16:55
11/22/17
11/22
16:55
11/22/17
16:55
Syndicate
Breaking Syndicate news story on Meridian Waste Solutions »

Meridian Waste Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$161.62

-0.67 (-0.41%)

16:50
11/22/17
11/22
16:50
11/22/17
16:50
Syndicate
Breaking Syndicate news story on Air Products »

Air Products files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOOT

Boot Barn

$13.49

-0.23 (-1.68%)

16:49
11/22/17
11/22
16:49
11/22/17
16:49
Syndicate
Breaking Syndicate news story on Boot Barn »

Boot Barn files $300M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$17.50

0.88 (5.29%)

, BCEI

Bonanza Creek

$32.14

0.46 (1.45%)

16:44
11/22/17
11/22
16:44
11/22/17
16:44
Hot Stocks
Icahn reports 13.51% stake in SandRidge Energy, intends to vote against Bonanza »

Icahn has read Fir Tree…

SD

SandRidge Energy

$17.50

0.88 (5.29%)

BCEI

Bonanza Creek

$32.14

0.46 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$17.50

0.88 (5.29%)

16:35
11/22/17
11/22
16:35
11/22/17
16:35
Hot Stocks
Icahn reports 13.51% stake in SandRidge Energy, intends to vote against Bonanza »

Icahn agrees with Fir…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$28.43

0.32 (1.14%)

, AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

16:32
11/22/17
11/22
16:32
11/22/17
16:32
Hot Stocks
Symantec selects Amazon Web Services to deliver cloud security »

Amazon Web Services, an…

SYMC

Symantec

$28.43

0.32 (1.14%)

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

16:30
11/22/17
11/22
16:30
11/22/17
16:30
Options
Preliminary option volume of 13.6M today »

Preliminary option volume…

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

16:26
11/22/17
11/22
16:26
11/22/17
16:26
Hot Stocks
Amazon Web Services announces Amazon ML Solutions Lab program »

Amazon Web Services, Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

NRIM

Northrim BanCorp

$34.75

-0.25 (-0.71%)

16:22
11/22/17
11/22
16:22
11/22/17
16:22
Hot Stocks
Northrim BanCorp announces CFO transition »

Northrim BanCorp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

, CERN

Cerner

$70.03

3.35 (5.02%)

16:21
11/22/17
11/22
16:21
11/22/17
16:21
General news
On The Fly: Top stock stories for Wednesday »

Stocks opened in positive…

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

CERN

Cerner

$70.03

3.35 (5.02%)

HPE

HP Enterprise

$13.10

-1.02 (-7.22%)

HPQ

HP Inc.

$21.34

-1.12 (-4.99%)

DE

Deere

$145.25

6.02 (4.32%)

ROK

Rockwell Automation

$191.02

-2 (-1.04%)

EMR

Emerson

$61.88

1.53 (2.54%)

AKZOY

AkzoNobel

$31.04

0.475 (1.55%)

AXTA

Axalta Coating

$35.50

1.63 (4.81%)

GME

GameStop

$17.37

0.64 (3.83%)

GES

Guess

$15.62

-2.33 (-12.98%)

IRBT

iRobot

$68.50

-4.57 (-6.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 11

    Dec

  • 18

    Mar

CHMI

Cherry Hill Mortgage

$18.51

0.06 (0.33%)

16:21
11/22/17
11/22
16:21
11/22/17
16:21
Syndicate
Breaking Syndicate news story on Cherry Hill Mortgage »

Cherry Hill Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$49.75

-0.23 (-0.46%)

16:20
11/22/17
11/22
16:20
11/22/17
16:20
Hot Stocks
Nektar names new CRDO, CMO and CSO »

Nektar announced several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
11/22/17
11/22
16:20
11/22/17
16:20
Options
Closing CBOE SPX and VIX Index summary for November 22nd »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VGZ

Vista Gold

$0.68

0.0069 (1.03%)

16:18
11/22/17
11/22
16:18
11/22/17
16:18
Syndicate
Vista Gold enters $10M ATM agreement with H.C. Wainwright & Co. »

Vista Gold announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPX

GP Strategies

$23.50

-0.2 (-0.84%)

16:17
11/22/17
11/22
16:17
11/22/17
16:17
Hot Stocks
GP Strategies announces $10M share repurchase increase »

GP Strategies Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

$NSD

NASDAQ Market Internals

16:17
11/22/17
11/22
16:17
11/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.